Ultra Violette Makes US Sunscreen History: First Bemotrizinol Launch in Over Two Decades
The FDA finalized approval of bemotrizinol in June 2026, the first new OTC-monograph UV filter in over two decades (GCI, Sept 2026; BoF, Sept 2026). Independent Australian brand Ultra Violette was first to market in the US with it (Unblock Screen SPF 50); a second product follows January 2027.
Why structural: A two-decade regulatory drought just ended, and an independent Australian brand — not P&G, L'Oréal, or Estée Lauder — moved first. Regulatory catch-up windows don't automatically favor incumbents with bigger R&D budgets.
Source: Global Cosmetic Industry, September 2026. Bemotrizinol is the first new OTC-monograph UV filter the FDA has approved in over two decades — Ultra Violette was first to market with it in the US.
Vegamour's Fall: $140M Peak Sales to a Foreclosure Sale in Four Years
Vegamour raised $80M from General Atlantic in 2021 and peaked at $140M in sales in 2022 (Beauty Independent, Sept 2026; PRNewswire, Sept 2026). Current sales sit at just over $50M, down more than half from peak. Belle Brands acquired the brand via foreclosure, another beauty turnaround acquisition; terms undisclosed.
Why structural: celebrity backing and growth-stage capital built hype, not durability. The brand outgrew its actual demand and never caught back up. Belle Brands' own language, "growing sustainably, thoughtfully and profitably," not "growth at any cost," is a direct rebuke of the model that built Vegamour.
Source: Beauty Independent, September 2026. Vegamour peaked at $140M in sales in 2022 after an $80M raise from General Atlantic — current sales sit at just over $50M, following a foreclosure sale to Belle Brands.
The US Reshoring Math Doesn't Add Up: McKinsey's $2T Capacity Gap
McKinsey Global Institute finds ~25% of US imports flagged as "Achilles' heel" vulnerabilities (McKinsey, May 2026). Domestic capacity needs to grow 30% overall to meet demand; over half of Achilles'-heel categories need 5x capacity. A full rebuild could cost $2T.
Why structural: Reshoring reads as decisive in political speeches; our read is the math says otherwise. No tariff regime can close a gap this size on a CPG company's timeline. Every beauty and household brand sourcing inputs from exposed suppliers carries that risk.
Source: McKinsey Global Institute, May 2026 ("Ramping Up Manufacturing in America?"). Building full domestic supply chains for trade-exposed products would require an estimated $2.0 trillion in new capital investment, against $3.7 trillion in current US manufacturing capital stock.
Shein's Hong Kong Debut: $5B Gone in a Week, Worst Post-IPO Stretch in Years
Shein's market cap fell from ~$26B to ~$21B in five trading days after its HK listing (Bloomberg, Aug 2026; Reuters, Aug 2026); shares closed 19% below offer price, the second-worst 5-day debut among HK IPOs raising $1 billion or more. Q1 net loss hit $99M versus $395M profit a year earlier; revenue growth slowed from ~21% to 8%.
Why structural: public markets rejected fast fashion's flagship IPO within days, pricing in tariff exposure and a stalled growth story at once. The same tariff and de-minimis exposure squeezing Shein sits upstream of every plastic-packaged CPG import too.
Source: Bloomberg, September 2026. Shein's market cap fell ~$5B in five trading days after its Hong Kong listing — shares closed 19% below offer price, the second-worst 5-day debut among HK IPOs raising $1B+.
Armani's Succession Clock: A €5–7B Valuation and a Deadline That May Not Be Binding
Giorgio Armani's will requires a ~15% stake sale 12–18 months after his death (September 2025), followed by a bigger sale or IPO (Bloomberg, Nov 2025; WWD, 2025). Bankers value the group at €5–7B; named potential buyers include LVMH, EssilorLuxottica, and L'Oréal. Sources say the deadline "is not strictly binding."
Why structural: one of the last major independent luxury houses is on a countdown to consolidation, buyers named in advance in the founder's will. The same conglomerate-consolidation logic, build or buy, is playing out in mass beauty and CPG right now.
Source: WWD, 2025. Giorgio Armani's will requires a ~15% stake sale within 12–18 months of his death — bankers value the group at €5–7B.